이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

T2 Biosystems 과거 수익 실적

과거 기준 확인 0/6

T2 Biosystems은 연평균 0.7%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 15.5%의 비율로 수입이 증가했습니다. 매출은 연평균 7.1%의 비율로 증가했습니다.

주요 정보

0.7%

수익 성장률

60.3%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	7.1%
자기자본 수익률	n/a
순이익	-636.1%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

Sep 22

T2 Biosystems' Survival Riddle

Aug 26

T2 Biosystems Q2 2022 Earnings Preview

Aug 12

T2 Biosystems drops 4% on Q2 guidance and 2022 outlook

Jul 06

A Roadmap To T2 Biosystems Story

Mar 08

수익 및 비용 분석

T2 Biosystems 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqCM:TTOO 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
31 Mar 24	7	-46	24
31 Dec 23	7	-50	25
30 Sep 23	11	-50	26
30 Jun 23	13	-52	27
31 Mar 23	17	-64	29
31 Dec 22	22	-62	31
30 Sep 22	24	-64	31
30 Jun 22	28	-61	32
31 Mar 22	28	-55	32
31 Dec 21	28	-49	29
30 Sep 21	29	-47	27
30 Jun 21	27	-44	24
31 Mar 21	23	-43	21
31 Dec 20	18	-47	22
30 Sep 20	13	-51	24
30 Jun 20	10	-54	25
31 Mar 20	9	-59	27
31 Dec 19	8	-59	27
30 Sep 19	7	-60	26
30 Jun 19	8	-57	26
31 Mar 19	10	-53	27
31 Dec 18	11	-51	26
30 Sep 18	10	-54	25
30 Jun 18	9	-58	24
31 Mar 18	6	-61	23
31 Dec 17	5	-62	23
30 Sep 17	4	-59	23
30 Jun 17	4	-57	23
31 Mar 17	4	-56	24
31 Dec 16	4	-55	24
30 Sep 16	4	-52	23
30 Jun 16	4	-51	23
31 Mar 16	4	-48	21
31 Dec 15	3	-45	19
30 Sep 15	2	-42	18
30 Jun 15	1	-40	16
31 Mar 15	0	-38	14
31 Dec 14	0	-36	11
30 Sep 14	0	-35	9
30 Jun 14	0	-33	7
31 Mar 14	0	-31	6
31 Dec 13	0	-28	5

양질의 수익: TTOO 은(는) 현재 수익성이 없습니다.

이익 마진 증가: TTOO 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: TTOO 은(는) 수익성이 없지만 지난 5년 동안 연간 0.7% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 TTOO 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: TTOO 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: TTOO 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

T2 Biosystems 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

T2 Biosystems, Inc. to Report Q1, 2024 Results on May 06, 2024

T2 Biosystems, Inc. to Report Q4, 2023 Results on Feb 15, 2024

T2 Biosystems, Inc. to Report Q3, 2023 Results on Oct 12, 2023

T2 Biosystems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Full year 2022 earnings: EPS misses analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. has withdrawn its Follow-on Equity Offering.

T2 Biosystems, Inc. to Report Q1, 2024 Results on May 06, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering.

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

T2 Biosystems Announces Agreement with CRG for Conversion of Term Loan into Equity to Regain Compliance

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

T2 Biosystems, Inc. to Report Q4, 2023 Results on Feb 15, 2024

T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group (Arlg) Pilot Study for Pneumonia Patients

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient new directors

T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference

Consensus revenue estimates decrease by 21%, EPS upgraded

T2 Biosystems Provides Nasdaq Compliance Update

T2 Biosystems, Inc. to Report Q3, 2023 Results on Oct 12, 2023

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

Price target increased by 58% to US$0.15

T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023

T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement

T2 Biosystems Receives Extension through November 20, 2023 to Comply with Nasdaq's Minimum Bid Price and Market Value of Listed Securities Requirements

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

T2 Biosystems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

T2 Biosystems, Inc. Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023

T2 Biosystems, Inc. announced that it has received $0.1 million in funding from CR Group L.P.

T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems Receives Letter from Nasdaq Regarding its Shares Failure to Comply with the Market Value of Listed Securities Required for Continued Listing on The Nasdaq Capital Market

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

Full year 2022 earnings: EPS misses analyst expectations

Consensus revenue estimates decrease by 50%, EPS upgraded

T2 Biosystems, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

T2 Biosystems, Inc. has completed a Follow-on Equity Offering.

T2 Biosystems, Inc. Announces Positive Results Upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel

T2 Biosystems Inc. Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation's LymeX Diagnostics Prize

Consensus EPS estimates fall by 15%

Price target decreased to US$1.85

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule

T2 Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

T2 Biosystems, Inc. Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel

T2 Biosystems, Inc. Announces Plan to Commercialize A Diagnostic Test for Early Lyme Disease

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

T2 Biosystems, Inc. Updates Revenue Outlook for the Full Year of 2022

T2 Biosystems, Inc. Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million

T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

T2 Biosystems' Survival Riddle

T2 Biosystems, Inc., Annual General Meeting, Oct 11, 2022

T2 Biosystems, Inc. announced delayed 10-Q filing

T2 Biosystems Q2 2022 Earnings Preview

T2 Biosystems, Inc to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus

T2 Biosystems, Inc. to Report Q2, 2022 Results on Aug 15, 2022

T2 Biosystems Receives Non-Compliance Notice from Nasdaq

T2 Biosystems, Inc. Receives Food and Drug Administration Breakthrough Device Designation for the T2Lyme Panel

Consensus forecasts updated

T2 Biosystems, Inc. Provides Preliminary Unaudited Revenue Guidance for the Quarter Ended June 30, 2022 and Provides Revenue Guidance for the Full Year 2022

T2 Biosystems drops 4% on Q2 guidance and 2022 outlook

T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule

High number of new directors